 An exploratory analysis of patent fencing in pharmaceuticals: The case of PDE5 inhibitorsChristian Sternitzke Research Policy, 2013, vol. 42, issue 2, 542-551 Abstract: Firms pursue a number of strategies to appropriate value, including patenting. In this paper I study patent fencing, a specific filing strategy to use multiple related patents to further enhance value appropriation. The paper addresses the pharmaceutical industry, which shows a high patenting propensity and strong lifecycle management activities leading to additional patent filings per drug. Building on an inductive case study, this paper explores the mechanisms behind patent fencing within a novel class of drugs. Patents with offensive blocking potential are primarily filed in the a later stage of the lifecycle and are tied to certain categories of patents with a low potential to substitute prior filings economically, while filing of patents with defensive blocking potential occurs more often in the early lifecycle stage. Finally, a model is developed on patent fencing in pharmaceuticals that builds on these patents’ characteristics. Keywords: Patent fencing; Drug lifecycle management; Blocking; Complementary patents; Substitutive patents (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:eee:respol:v:42:y:2013:i:2:p:542-551 DOI: 10.1016/j.respol.2012.11.003 Access Statistics for this article Research Policy is currently edited by M. Bell, B. Martin, W.E. Steinmueller, A. Arora, M. Callon, M. Kenney, S. Kuhlmann, Keun Lee and F. Murray More articles in Research Policy from Elsevier |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.